Helical closes $10M seed to turn bio foundation models into systems
Helical, a London-based pharma AI startup, has raised $10 million in a seed round led by redalpine to expand its platform for bio foundation models. The company's platform is already in production with multiple top-20 global pharma companies, including Pfizer, and aims to accelerate drug discovery timelines.
Helical, a pharma AI startup, has raised $10 million in a seed round. The company's platform helps pharma companies use bio foundation models to discover new drugs. Helical's platform has two surfaces: a Virtual Lab for biologists and a Model Factory for ML engineers. The company is already working with top-20 pharma companies, including Pfizer. Helical's platform aims to accelerate drug discovery timelines, which can currently take over a decade. The company plans to use the funding to expand its platform and grow its team.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.